This will be be its fifth location in Ireland
|RSS Feeds||News Alerts||Newsletter|
Generic pharmaceutical company Aspen has announced its decision to make Dublin its centre of excellence for a range of global and EMEA activities and to create an additional 44 high quality jobs bringing its total workforce in Ireland to 58.
The investment, which is being supported by the IDA, was announced this morning by Minister for Jobs, Enterprise and Innovation, Richard Bruton TD.
The company first established an operation in Ireland in 2010 and this has now become Aspen’s European marketing and supply chain headquarters. In addition, the company is now establishing a global regulatory, pharmacovigilance, quality assurance and supply projects centre of excellence in Citywest..
Aspen is one of the largest generic global pharmaceutical companies and the largest producer of anti-retroviral (HIV) drugs in South Africa.
“Ireland provides for us a workforce with the specialised skills we require and a strong regulatory and business environment,” said Aspen group chief executive, Stephen Saad. “I would like to thank the Irish Government and IDA Ireland for their support and look forward to the future development of Aspen in Ireland."
“Aspen’s decision to locate this operation here adds to Ireland’s cluster of life science companies and will add to our reputation as a leading centre for this sector,” said Barry O’Leary, CEO of IDA Ireland. “A key member of this cluster in Ireland is GlaxoSmithKline which owns a 20pc share of Aspen.
“Ireland offers South Africa’s largest pharmaceutical company a strategic location from which to support its ongoing expansion and grow its sales across Europe.”
“Pharmaceuticals is a major sector of strength for Ireland, with nine out of the top ten global companies located here,” said Minister Bruton. “However a key part of the Government’s plan for jobs and growth is targeting the areas of growth within what is a changing sector – in particular, generics. Today’s announcement that Aspen, one of the world’s leading generic pharmaecutical companies is expanding its operations here is very welcome news.”